<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Naobios 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=46673></link><description><![CDATA[Naobios 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sun, 03 May 2026 17:50:26 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2024/10/1028147215_20241030135041_6806383944.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Naobios and Sumagen Successfully Optimize HIV Vaccine Candidate for Industrial Production]]></title><link>https://www.newswire.co.kr/newsRead.php?no=999691</link><description><![CDATA[NANTES, France--(Business Wire/Korea Newswire)--Naobios, a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production of clinical batches of virus-based products, and Sumagen Canada Inc (Sumagen), a Korean-Canadian biotechnology company part of CreoSG Co., Ltd, today announce the production of HIV-1 vaccine candidate at bench scale.  This ke...]]></description><pubDate>Wed, 30 Oct 2024 14:25:00 +0900</pubDate></item><item><title><![CDATA[나오바이오스와 수마젠 - 산업 생산을 위한 HIV 백신 후보 물질 최적화 성공]]></title><link>https://www.newswire.co.kr/newsRead.php?no=999695</link><description><![CDATA[낭트, 프랑스--(Business Wire/뉴스와이어)--바이러스 기반 제품의 임상 배치에 대한 바이오프로세스 개발 및 GMP 생산을 제공하는 위탁개발생산조직(Contract Development and Manufacturing Organization, CDMO)인 나오바이오스(Naobios)와 CreoSG Co., Ltd.의 한국-캐나다 생명공학 회사인 수마젠 캐나다(Sumagen Canada Inc)(수마젠)가 HIV-1 백신 후보물질을 벤치 스케일(bench scale)로 생산한다고 발표했다.  일...]]></description><pubDate>Wed, 30 Oct 2024 14:25:00 +0900</pubDate></item></channel></rss>